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The incidence of asthma has escalated over
the past 20 years. Increasingly, initial asthma
episodes are observed early in life (Holt 1998;
Weiss 1998). In 2004, nearly 30% of the
30 million diagnosed asthmatics in the
United States were < 18 years of age. The
highest asthma prevalence rate (148/1,000)
exists in 5- to 17-year-olds (American Lung
Association 2006). Despite the often early
onset of this disease, chronic adult asthmatics
comprise the majority of asthma patients. 
Stresses in the fetal environment can pro-
mote early onset of chronic adult diseases.
Initial epidemiologic studies related maternal
nutritional deficits to low live birth weights
and to premature cardiovascular disease in
adult human offspring (reviewed by Barker
2002). In humans, neurologic response to fetal
stress has been recently reviewed (Amiel-Tison
et al. 2004). In experimental studies, fetal ane-
mia in sheep (Davis et al. 2005) and hypoxia
in pregnant rats (Li et al. 2004) have resulted
in chronic disease in adult offspring. In preg-
nant mice, viral infection (Niklasson et al.
2006), pesticide treatment (Cory-Slechta et al.
2005), and environmental tobacco smoke
(ETS) exposure (Yang et al. 2004) have also
resulted in chronic adult disease in offspring.
Exposure to ETS has been associated with
exacerbated asthmatic responses in children
(Gilliland et al. 2000; Lindfors et al 1999;
Mannino et al. 2001). Altered lung function,
increased risk of asthma, and persistent lung
function deﬁcits in children have been linked
with in utero exposure to maternal smoking
and/or postnatal exposure to ETS (Gilliland
et al. 2000, 2001, 2003; Li et al. 2000;
Zlotkowska and Zejda 2005). The synergistic
action of tobacco smoke exposure with sensi-
tization to nontobacco allergens may increase
the prevalence of allergy and asthma
(Oryszczyn et al. 2000). Detailed experimen-
tal studies focused on proasthmatic responses
resulting from in utero ETS exposure com-
bined with postnatal exposure to nontobacco
antigens have not been reported. 
In rodent models of allergic asthma,
ovalbumin (OVA) is a commonly employed
antigen for eliciting allergic responses.
Sensitization by intraperitoneal (ip) injec-
tion, followed by inhalation challenge with
OVA elicits expansion of the T helper-2
(Th2) lymphocyte population. Production
of Th2 cytokines follows, leading to airway
hyperresponsiveness (AHR) and inflamma-
tion characterized by eosinophilia and OVA-
speciﬁc IgE (Zhang et al. 1997).
This sensitization/challenge protocol fails
to mimic the typical human experience of
aerosol-only sensitization and challenge (Bice
et al. 2000; Persson et al. 1997). However,
aerosol-only OVA exposure of mice results in
little or no OVA-speciﬁc serum IgE, and no
eosinophilic inﬂammatory response. This has
been attributed to the induction of immuno-
logic tolerance speciﬁcally affecting IgE pro-
duction (Astori et al. 2000; Holt et al. 1981;
McMenamin and Holt 1993; Seymour et al.
1998). Interleukin (IL)-10 from regulatory
T cells in the lung (Akbari et al. 2001) favors
the production of IgG1 antibodies and
inhibits isotype switching to IgE (Jeannin
et al. 1998). This, combined with the induc-
tion of T-cell tolerance (Buer et al. 2005),
protects most individuals from developing
allergic airway diseases to commonly encoun-
tered allergens (Tsitoura et al. 2000).
Although genetic polymorphisms and under-
lying regulatory faults in IL-4 and IL-13 pro-
duction can impair this safety mechanism
(Heinzmann et al. 2000; Howard et al. 2001;
Izuhara et al. 2000; Seah et al. 2001;
Shirakawa et al. 2000;), environmental expo-
sures might also contribute to loss of airway
tolerance.
We designed experiments to simulate the
respiratory consequences to offspring of
pregnant, nonsmoking women exposed daily
to ETS. We combined daily ETS exposure
of pregnant BALB/c mice with postnatal
OVA inhalation to test the hypothesis that
in utero ETS exposure can alter postnatal
respiratory and immune responses to non-
tobacco allergens. 
We posed the following questions. Is
in utero exposure to ETS sufﬁcient to:
• Compromise respiratory responses in young
mice? In adults?
• Promote cytokine production in OVA-
exposed mice? 
• Inﬂuence AHR or lung histopathology fol-
lowing OVA provocation?
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BACKGROUND: Fetal stress has been linked to adult atherosclerosis, obesity, and diabetes.
Epidemiology studies have associated fetal exposure to maternal smoking and postnatal exposure to
environmental tobacco smoke (ETS) with increased asthma risk. 
OBJECTIVE: We tested the hypothesis, in a mouse model of asthma, that in utero ETS exposure
alters airway function and respiratory immune responses in adults. 
METHODS: Pregnant Balb/c mice were exposed daily to ETS or HEPA-ﬁltered air (AIR). Offspring
inhaled aerosolized ovalbumin (OVA) or saline in weeks 7–8. Regardless of whether they inhaled
OVA or saline, mice were sensitized by OVA injections in weeks 11 and 13 followed by OVA
aerosol challenge in weeks 14–15. At three time points, we assessed OVA-speciﬁc serum immuno-
globins, bronchoalveolar lavage cells and cytokines, lung and nasal histopathology, and airway
hyperresponsiveness (AHR). 
RESULTS: At 6 weeks, we found no signiﬁcant differences between in utero ETS and AIR mice. At
10 weeks, following OVA aerosol, ETS mice displayed greater AHR than AIR mice (α = 0.05),
unaccompanied by changes in histopathology, cytokine profile, or antibody levels. At 15 weeks,
mice that had inhaled saline in weeks 7–8 developed airway inﬂammation: eosinophilia (α = 0.05),
interleukin-5 (α = 0.05), and AHR (α = 0.05) were greater in ETS mice than in AIR mice. Mice
that had inhaled OVA in weeks 7–8 demonstrated no airway inﬂammation after sensitization and
challenge. 
CONCLUSION: In utero ETS exposure exacerbates subsequent adult responses to initial allergen
exposure. 
KEY WORDS: airway hyperresponsiveness, allergens, asthma, environmental tobacco smoke (ETS),
in utero, tolerance. Environ Health Perspect 115:548–555 (2007). doi:10.1289/ehp.9780 available
via http://dx.doi.org/ [Online 4 January 2007]• Interfere with establishment of aerosol toler-
ance to OVA or with production of OVA-
speciﬁc antibodies?
Materials and Methods
Animal protocols. We housed and handled
Balb/c mice (Harlan, Indianapolis, IN),
according to the NIH Guide for the Care and
Use of Laboratory Animals (Institute of
Laboratory Animal Resources 1996). The
Louisiana State University institutional ani-
mal care and use committee approved all ani-
mal procedures. Animals were treated
humanely and with regard to alleviation of
suffering. Mice, on a 12-hr light/dark cycle,
had food and water ad libitum except when in
the exposure chambers. We began breeding
8-week-old mice (1 male/2 females) the
evening before initiation of ETS exposure.
After exposures ended (day 19), we housed
pregnant mice in separate cages until weaning
of offspring (day 21 after birth). 
ETS exposures. Sidestream smoke, which
comprises approximately 90% of ETS, served
as a surrogate for ETS (Bowles et al. 2005;
Penn and Snyder 1993). A 30-port smoking
machine (AMESA Technologies, Geneva,
Switzerland) generated smoke from 2R4F ﬁl-
tered research cigarettes (University of
Kentucky). We diluted ETS with HEPA-fil-
tered air (AIR) to establish a suspended parti-
cle load of 10 mg/m3. A MIRAN sapphIRe
infrared spectrometer (The Foxboro Co.,
Foxboro, MA) and a DustTrak particle moni-
tor (STI, St. Paul, MN) continuously moni-
tored carbon monoxide and total suspended
particle levels, respectively, in exposure cham-
bers. Gravimetric analyses were performed
every 2 hr by weighing 0.45-mm membrane
filters (Gelman, Ann Arbor, MI) through
which measured amounts of smoke had
passed. We exposed 8-week-old mated mice
to ETS or AIR (14 air changes/hr, 5 hr/day,
19 consecutive days) in 1.3-m3 stainless steel
and plexiglass dynamic exposure chambers
(71° ± 1.5°F; relative humidity, 53 ± 3%).
No offspring were exposed to ETS after birth. 
Aerosol exposures. We exposed mice (7–8
weeks of age) in a 16-compartment, 16.7-L
plexiglass inhalation exposure chamber to
aerosolized sterile saline or 1% (wt/vol) OVA
(Grade V > 98% pure; Sigma Chemical Co.,
St. Louis, MO) in saline (20 min/day; 10 days).
A ﬂow rate of 4 L/min was maintained through
an Airlife sidestream high-efﬁciency nebulizer
(Cardinal Health, Dublin, OH). 
OVA sensitization/challenge. We sensitized
mice to OVA by ip injections (80 µg OVA in
2.0 mg alum), one each at 11 and 13 weeks of
age. OVA challenge included three 20-min
inhalation exposures to 1% OVA in saline,
every other day at 14 weeks of age, plus a
20-min exposure 1 day before sacrifice at
15 weeks. 
Bronchoalveolar lavage cell and fluid
collection. Following euthanasia, we lavaged
the right lung of each mouse 4 times with
0.3 mL warm phosphate-buffered saline
(PBS) and resuspended the centrifuged bron-
choalveolar lavage (BAL) cell pellet in PBS for
BAL differential counts (200 cells). Smears
were stained with a modiﬁed Wright’s stain.
The BAL supernatant was stored at –80°C for
cytokine analyses. 
Creation of standard sera for isotype-
specific ELISAs. We pooled and assayed sera
from sensitized/challenged BALB/c mice for
OVA-specific IgG1, IgG2a, and IgE by iso-
type-specific ELISA at varying dilutions
(IgG1, 1:10,000; IgG2a, 1:100; IgE, 1:10).
The pooled sera constituted a standard in
subsequent isotype-specific ELISAs on test
sera. The isotype-specific optical density
(OD) value from the isotype standard was set
as one ELISA unit (EU). 
OVA-specific IgG1, IgG2a, and IgE
ELISAs. We used isotype-specific ELISAs to
quantitate OVA-specific antibody levels in
sera (Seymour et al. 1997) from blood
obtained at sacrifice. For IgG1 and IgG2a,
OVA-coated (100 µL/well of 0.1% OVA)
96-well ﬂat bottom plates (Fisher, Pittsburgh,
PA) captured OVA-specific antibodies.
Horseradish peroxidase (HRP)-conjugated rat
anti-mouse IgGl or IgG2a antibodies (BD-
Pharmingen, San Diego, CA) marked cap-
tured antibody. For OVA-specific IgE
detection, 96-well Immulon4 plates (Thermo
Electron Corp., Waltham, MA) coated with
monoclonal rat anti-mouse IgE (5 µg/mL in
PBS, 100 µL/well; BD-Pharmingen) captured
serum IgE. Biotinylated-OVA (2.5 mg/mL;
Pierce EZ-Link LC; Pierce, Rockford, IL) and
HRP-streptavidin (Pierce) marked captured
OVA-specific antibody. For all ELISAs,
3,3´,5,5´- tetramethylbenzidine substrate
(100 µL/well) detected marked antibodies. We
used a standard ELISA reagent kit (OptEIA
Reagent Set B; BD-Pharmingen) and con-
verted OD450 readings of the samples to EU.
Histopathologic analysis of lungs. Following
BAL collection, we perfused lungs with 0.3 mL
freshly prepared 0.02 M periodate–0.1 M
lysine–0.25% paraformaldehyde (PLP) ﬁxative
in phosphate buffer (pH 7.4), then excised
and stored the lungs in PLP for 24–48 hr. We
sectioned the cranial, middle, and caudal lobes
of the right lung along the plane of each lobar
bronchus. Following postfixation in 70%
ethanol, we embedded samples in parafﬁn and
dehydrated them directly in graded alcohols to
eliminate further exposure to formaldehyde.
We stained 3-to 4-µm sections with hema-
toxylin and eosin. We used a seven-category
weighted scoring system (bronchus-associated
lymphoid tissue, lymphocytes, plasma cells,
eosinophils, neutrophils, mucus metaplasia,
and total cellularity) for histopathologic evalu-
ation of lung sections (Bowles et al. 2005). A
board-certiﬁed veterinary pathologist, blinded
to the treatments, evaluated histopathologic
samples. A higher score (maximum score =
25) indicates greater tissue responsiveness.
Histochemical analysis of nasal tissue. We
ﬁxed heads in buffered-neutral formalin, then
decalcified them for 3 days in 15% formic
acid before sectioning (Bahnemann et al.
1995). A pathologist, blinded to the treat-
ments, scored nasal sections for inﬂammation
by cell type and epithelial changes, according
to the type of epithelium (squamous, respira-
tory, and olfactory). 
Cytokine quantitation in BAL ﬂuid. We
used a fluorescence-based murine Th1/Th2
cytometric bead array assay (BD-Pharmingen)
to analyze aliquots of BAL supernatants 
on a BD FACSCaliber instrument (BD-
Pharmingen). The cytokines included in the
assay were IL-2, IL-4, IL-5, tumor necrosis
factor-α (TNF-α), and interferon-γ (IFN-γ).
Their limits of detection were 5.0, 5.0, 5.0,
2.5, and 6.3 pg/mL, respectively. A single
bead assay for IL-13 had limits of detection
of 7.3 pg/mL.
Pulmonary function testing. We assessed
AHR in unrestrained mice by whole body
plethysmography (Buxco, Troy, NY). Data
were expressed as a dimensionless value,
Penh, or “enhanced pause” (Hamelmann
et al. 1997b). Following acclimation and
aerosol saline exposure, we challenged mice
with graded doses (1.56–50.0 mg/mL) of
nebulized methacholine (Sigma) to assess
AHR. We recorded postexposure Penh values
over 5 min for each dose. 
Although some concern has been expressed
regarding the limitations of Penh measure-
ments obtained via unrestrained plethysmogra-
phy (Lundblad et al. 2002), there are many
reports of strong correlations between increases
in Penh values and bronchoconstriction
demonstrating that Penh serves as a reliable
monitor of changes in lung mechanics
(Delorme and Moss 2002; Hamelmann et al.
1997a; Singh et al. 2003). 
Statistical analysis. We used the SAS statis-
tical package (version 9.1.3; SAS Institute,
Inc., Cary, NC) GLM (general linear model)
procedure for all analyses. In addition, where
appropriate we conducted an analysis of vari-
ance (ANOVA) by sampling time with various
end points (BAL cells, histopathology scores,
cytokine levels) as the response variables, and
treatment, sex, and treatment–sex interaction
as effects in the model. We analyzed antibody
data by a one-way ANOVA across treatment
groups and plethysmograph data in an
ANOVA on repeated measures. In considering
limits of detection, we ranked cytokine data
and carried out a Kruskal-Wallis test (one-way
ANOVA) on the ranks. When the overall
model indicated significance, we conducted
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HSD (honest significant difference) test for
main effects comparisons (Siegel 1956; Steele
and Torrie 1980). Pair-wise comparisons of
signiﬁcant interaction effects were conducted
with t-tests of least square (adjusted) means. In
all cases, we considered comparisons signiﬁcant
at α = 0.05.
To test the trend and relationship of one
treatment group to another, we paired
(blocked) the means of the various response
variables and compared the two treatment
groups with respect to these paired mean val-
ues. The null hypothesis was that the treat-
ment groups were the same based on the
paired comparisons. We used the Wilcoxon
matched-pairs test, Pearson correlation test,
and a regression analysis on the matched
groups to examine the potential trend. We
considered all analyses signiﬁcant at α = 0.05
(Neter and Wasserman 1974). 
Exposure and sampling schedule We ran-
domly assigned mated females to gestational
ETS- or AIR-exposure groups (a timeline
showing the exposure and sampling schedule
is presented in Figure 1). At weaning, mice
were segregated by sex with no more than four
or ﬁve mice per cage. We sacriﬁced groups of
in utero ETS and AIR mice at 6 weeks of age
to determine effects of in utero ETS exposure
on lung responses of young mice (Figure 1A).
Half of the remaining mice inhaled OVA
[ETS/OVA (EO), AIR/OVA (AO)] aerosol at
7–8 weeks of age. The other half inhaled
saline aerosol [ETS/saline (ES), AIR/saline
(AS)]. Each of these groups contained
35–39 mice representing 6–10 litters. We
sacriﬁced mice in each group at 10 weeks of
age to determine the effects of in utero ETS
exposure, plus subsequent OVA inhalation,
on lung responses of young adult mice
(Figure 1B). We sacrificed the remaining
mice, following OVA-sensitization and -chal-
lenge, at 15 weeks of age (Figure 1C) to deter-
mine the effects of in utero ETS exposure on
responses to OVA sensitization [ETS/saline/
OVA (ESO), AIR/saline/OVA (ASO)] and
OVA tolerance [ETS/OVA/OVA (EOO),
AIR/OVA/OVA (AOO)]. We analyzed anti-
body levels, BAL cytology and Th1/Th2
cytokine levels, lung and nasal histopathology,
and pulmonary function at all time points.
Results
Forty to ﬁfty percent of ETS and AIR females
had litters. There were no significant differ-
ences in delivery rate or litter size between
ETS and AIR dams. However, in utero ETS
offspring were of slightly lower birth weight
and experienced a higher mortality rate
between birth and 3 weeks of age than did
in utero AIR offspring (12% vs. 2%;
α = 0.05). Thereafter, survival rates were
similar, and any inequity in weight or growth
rate was lost. In both groups, the male:female
offspring ratio was approximately 1:2. At
weaning, there were 89 in utero ETS offspring
from 19 litters and 94 in utero AIR offspring
from 19 litters. 
We detected no upper respiratory tract
changes, including evidence of inﬂammation
or congestion, in any treatment groups at any
time point during this study, as determined by
Penn et al.
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Figure 1. Experimental timeline for prenatal and postnatal treatments and sacrifices showing (A) ETS
exposure, (B) ETS exposure plus OVA inhalation, and (C) ETS exposure plus OVA inhalation plus ip OVA
challenge. Times are expressed relative to birthdate of offspring. GD, gestation day. 
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Figure 2. In utero ETS exposure has no overall effect in 6-week-old Balb/c mice (A) and increases AHR in
10-week-old mice (B). Mice received graded doses (1.56–50 mg/mL) of nebulized methacholine, and AHR,
expressed as Penh values, was determined by noninvasive, whole-body plethysmography. In (A) at the two
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these points were not sufﬁcient to create a signiﬁcant difference in overall response curves. In (B), in utero
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Figure 3. In utero ETS exposure has no effect on
OVA-speciﬁc serum antibody (IgG1, IgG2a, IgE) levels
in 15-week-old mice. Bars represent mean ± SE.
*Signiﬁcantly different from both ASO and ESO (α = 0.05). evaluation of nasal histopathology. We found
no differences in any end points between male
and female offspring at any time point (data
not presented). 
Six-week-old mice. Exposure to ETS
in utero, without any subsequent treatment,
had no overall effect on pulmonary function,
although at the two highest methacholine
doses a signiﬁcant AHR increase (p ≤ 0.017)
was noted in ETS mice (Figure 2A). There
were no measurable effects for any of the
other end points (data not presented) in
6-week-old mice. 
Ten-week-old mice. At 10 weeks of age,
EO and AO mice had consistently differing
OVA-specific antibody profiles, IgG1
(EO > AO) and IgG2a (AO > EO). These dif-
ferences however, were not significant for
either isotype (data not shown). We detected
no OVA-speciﬁc IgE in sera of OVA-aerosol
exposed mice. As expected, we detected no
OVA-speciﬁc IgG1, IgG2a, or IgE in control
mice regardless of whether their in utero expo-
sure was to ETS (ES) or AIR (AS). 
With the exception of TNF-α, all cytokine
levels were below limits of detection for all
groups at 10 weeks of age. TNF-α was signiﬁ-
cantly higher (p < 0.05; data not shown) in AO
mice compared with other groups. Aerosol
OVA exposure at 7–8 weeks of age had little
overall effect on BAL cell distribution at
10 weeks. As at 6 weeks of age, BAL cells in all
groups were mostly mononuclear cells
(94–100%). Lung histopathology scores were
low, ranging from 6.47 to 7.15. There were no
signiﬁcant differences between any groups in
BAL cell distributions or lung histopathology. 
Ten-week-old AO mice demonstrated sig-
niﬁcantly increased AHR compared with AS
mice (Figure 2B) at methacholine levels
≥ 12.5 mg/mL. This response was ampliﬁed in
mice exposed to ETS in utero. Ten-week-old
EO mice exhibited signiﬁcantly elevated AHR
compared with all other groups, at metha-
choline levels ≥ 6.25 mg/mL. At the highest
methacholine concentration (50 mg/mL), the
AHR of EO mice was 2 to 4 times greater than
that of other groups. Overall response curves
were not signiﬁcantly different between ES and
AS mice. However, at the highest metha-
choline level, ES mice had increased AHR
(p < 0.0001) relative to AS mice. 
Fifteen-week-old mice. We analyzed all
remaining mice for the effects of in utero ETS
exposure on responses to the OVA sensitiza-
tion and challenge. There were no signiﬁcant
differences in OVA-speciﬁc IgG1, IgG2a, and
IgE levels between groups of mice exposed to
OVA for the first time (ASO and ESO) or
between groups previously exposed to OVA
(AOO and EOO; Figure 3). In the former,
there were signiﬁcantly lower levels of OVA-
speciﬁc IgG2a and signiﬁcantly higher OVA-
speciﬁc IgE levels than in the latter. 
All measured cytokines were higher in
ESO mice than in ASO mice, although not
significantly (Table 1). IL-4, IFN-γ, and
TNF-α were signiﬁcantly lower in EOO mice
compared with AOO mice. Levels of IL-4,
IL-5, IL-13, and TNF-α were significantly
lower in EOO mice than in ESO mice. IL-13
and IL-5 were consistently higher in mice
exposed to OVA for the ﬁrst time (ESO and
ASO) than in mice previously exposed to
OVA (EOO and AOO). Levels of IL-2 did
not differ between any groups. 
Eosinophil levels in BAL fluid were
significantly higher in ESO and ASO mice
than in AOO and EOO mice (Figure 4).
Eosinophil and polymorphonuclear leukocyte
levels were signiﬁcantly lower in EOO com-
pared with AOO mice. Mononuclear cells
accounted for > 96% of the BAL ﬂuid cells in
EOO mice. No BAL cell differences were
found between AOO and ASO mice. 
Increased lung inﬂammation was evident
in both ESO and ASO mice (Figure 5). Lung
inflammation in mice previously exposed to
OVA (EOO and AOO) was reduced com-
pared with that in mice exposed to OVA for
the first time (ESO and ASO). Again, the
largest difference was between ESO and EOO
mice. There were no differences between
EOO and AOO or between ESO and ASO. 
There was increased AHR, as expected, at
methacholine levels of 12.5–50 mg/mL in
mice exposed to OVA for the ﬁrst time (ESO
and ASO; Figure 6) compared with mice that
had previous OVA-exposure (EOO and
AOO). However, AHR in ESO mice was
also significantly elevated compared with
ASO mice. Overall, the most striking differ-
ences in AHR were between the responsive
ESO mice and the relatively nonresponsive
EOO mice. The EOO mice also exhibited
signiﬁcantly attenuated AHR compared with
AOO mice.
As we analyzed our data, we noted what
appeared to be trends in overall treatment
group responses. To further investigate these
trends, we identiﬁed 11 end points that have
a direct relationship to airway inflammation
and/or Th2 responses (i.e., they all increase as
inﬂammation and/or Th2 responses increase).
We compared paired group means for these
end point measures in both in utero ETS and
in utero AIR mice using speciﬁc tests for trend
(Table 2). Analyses confirmed significant
trends in the relationship between ETS and
AIR mice.
Discussion
We determined no differences between sexes in
responses of mice exposed in utero to ETS and
subsequently to OVA. There are no equivalent
experimental asthma studies with which to
compare these responses directly, because the
ETS/OVA exposure schedule we followed has
not been reported previously in a mouse model
of asthma. There are, however, reports of dif-
ferences between males and females with
regard to asthma end points after postnatal
ETS and OVA exposures in Balb/c mice
(Melgert et al. 2005; Seymour et al. 2002).
Also, differences between sexes have been
observed in humans with regard to asthma end
points. More adult females than males have
asthma, although this relationship is reversed
in children (American Lung Association 2006).
Mortality due to asthma is higher among
human females than among males. 
Our studies were designed to address three
distinct, but related issues in a mouse model of
asthma: a) whether there are any long-term,
asthma-related consequences arising from
in utero exposure to ETS, in the absence of
any subsequent lung provocation; b)w h a t
effects, if any, in utero ETS exposure has on
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Table 1. Ranked cytokine measurements in BAL ﬂuid of 15-week-old mice. 
IL-13 IL-4 IL-5 TNF-α IFN-γ IL-2
AOO (n = 21) 1.05* 42.76** 7.24* 31.45** 37.21** 9.07
EOO (n = 18) 1.00* 20.14* 1.17* 11.56*  18.36* 2.83
ESO (n = 14) 4.57** 48.82** 26.43**  31.96** 35.61 7.54
ASO (n = 19) 3.18 39.79** 18.37** 21.53 35.40 4.00
Data were ranked to account for values below the limit of detection. Ranked data were analyzed using a Kruskal-Wallis
test (one-way ANOVA). When significant, Tukey’s HSD test was used for post hoc comparisons of effects. For each
cytokine, values marked with one asterisk (*) are signiﬁcantly different from those with ** (α = 0.05); values without an
asterisk are not signiﬁcantly different from any other value.
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Figure 4. In utero ETS exposure affects BAL cell
differentials in 15-week-old mice. Abbreviations:
EOS, eosinophil; MONO, monocyte; PMN, poly-
morphonuclear leukocyte. A 200-cell differential
count was performed on BAL cells from each
mouse in every group. Bars represent mean ± SE. 
*Significant difference between all groups, **significant
difference between EOO and both AOO and ASO, and #sig-
nificant difference between ESO and both AOO and EOO;
α = 0.05.adult responses to sensitization and challenge
with an otherwise innocuous antigen (OVA);
and c) whether in utero exposure to ETS
affects establishment of aerosol tolerance. 
Human epidemiologic studies suggest
that in utero ETS exposure may be sufﬁcient
to increase the incidence and severity of
asthma. Temporal associations between
tobacco smoke exposures of fetuses/young
children and subsequent altered lung responses
have been investigated. The association
between smoke exposure and subsequent
decreases in forced expiratory volume (a mea-
sure of lung function) was stronger when
exposure was prenatal (Cunningham et al.
1994). The asthma risk for children exposed
in utero via maternal smoking was > 2 times
that for children receiving postnatal ETS
exposure (Cunningham et al. 1996). 
Both postnatal ETS exposures and in utero
smoke exposures have been linked with
decreased lung function in school-age children
(Gilliland et al. 2000), especially in those
already diagnosed with asthma (Li et al. 2000).
Furthermore, in utero exposure to maternal
smoking, without subsequent ETS exposure,
was associated with increased asthma and
wheezing in young children. Postnatal ETS
exposure was, however, associated with
increased wheezing but not with increased
asthma prevalence (Gilliland et al. 2001). In
contrast, in the absence of known allergen
exposure, postnatal exposure to ETS was more
strongly correlated with increased AHR and
wheezing than was ETS exposure during preg-
nancy (Lindfors et al. 1999). 
In a 2001 review of the literature, Lodrup
Carlsen and Carlsen (2001) concluded that 
[B]oth in-utero and, to some degree, passive (envi-
ronmental) tobacco smoke (ETS) exposure adversely
affect pulmonary function, and predispose to asthma
symptoms.
A questionnaire-based survey of parents of
≥ 4,000 children revealed that in utero expo-
sure to maternal smoking was a strong risk
factor for wheezing and physician-diagnosed
asthma in young children (Lannero et al.
2006). Neonates of nonsmoking mothers
exposed to ETS during pregnancy had higher
serum levels of cotinine, (a major nicotine
metabolite) than their mothers (Perera et al.
2004). This tendency to bioaccumulate
smoke components could cause in utero ETS-
exposed children to be particularly susceptible
to respiratory problems. 
Rodent studies have confirmed that
in utero exposure to ETS can be critical to
subsequent respiratory and immune system
responses. Rats exposed to sidestream smoke
for the first 100 days of life displayed no
altered lung function or reactivity to metha-
choline (Joad et al. 1993). In contrast, female
rats exposed continually to sidestream smoke
in utero from gestation day (GD) 3 through
week 10 after their birth, demonstrated a
24% decrease in lung dynamic compliance
and a 20-fold increase in methacholine reac-
tivity compared with rats exposed to smoke
only during gestation or only after birth (Joad
et al. 1995). The timing effect was further
reﬁned when rats were exposed to ﬁltered air
or sidestream smoke (1 mg/m3) in utero from
GD3 through day 21 after their birth (Joad
et al. 1999). At 8 weeks of age, they displayed
signiﬁcant increases in AHR and pulmonary
artery pressure and decreases in dynamic
compliance compared with controls. In a
recent report, Ng et al. (2006) associated
increased tumor incidence and growth with
in utero exposures to mainstream smoke.
Offspring of B6C3F1 mice exposed in utero
to smoke from GD4 to birth, were injected
with lymphoma cells at 5 and 10 weeks of
age. Males exhibited a > 2-fold increase in
tumor incidence and more rapid tumor
growth relative to controls. This was accom-
panied by decreased cytotoxic T-lymphocyte
activity without changes in natural killer cell
activity, cytokine levels, lymphoid organ his-
tology, or immune cell subpopulations.
Our results from 6-week-old mice indi-
cate that in utero ETS exposure without fur-
ther lung challenge has no observable effect
on pulmonary function or histology. The
only signiﬁcant ﬁnding at this age is elevated
AHR in ETS mice at the two highest metha-
choline challenge doses. These points are
insufﬁcient to produce a signiﬁcant difference
in the total response curve. However, they
may reﬂect an ETS-induced AHR sensitivity
that becomes more apparent with additional
lung stress or challenge. 
At 10 weeks of age, groups of both ETS
and AIR mice were exposed to aerosol OVA in
the absence of any adjuvant, including
lipopolysaccharide, to produce mice that were
tolerant to airway inﬂammation by OVA sensi-
tization and challenge. The antibody proﬁles of
these animals were as expected. There were sig-
nificant OVA-specific antibody responses
(IgG1 and IgG2a) indicating recognition and
allergen-speciﬁc activation, but no indication
of signiﬁcant effector response (eosinophilia,
Penn et al.
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Figure 5. Photomicrographs from the median histopathology score mouse of each group: (A) ASO,
(B) AOO, (C) ESO, and (D) EOO. Inﬂammatory responses are most pronounced in ESO mice and least pro-
nounced in EOO mice at 15 weeks of age.  Bars = 150 µm.
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Figure 6. In utero ETS exposure alters AHR in
15-week-old Balb/c mice transiently exposed to
methacholine 1 day after OVA challenge. Bars rep-
resent mean ± SE.
*Signiﬁcant difference between ESO and all other groups
(p < 0.0001). **Significant difference between ESO and
both ASO and EOO (p ≤ 0.013) and a signiﬁcant difference
between EOO and both AOO and ESO (p ≤ 0.023). EOO
differed significantly from ASO only at 25 mg/mL metha-
choline; this one point did not create a significant differ-
ence in overall response curves. mucus hyperplasia, cytokine elevation, or
OVA-speciﬁc IgE). These ﬁndings are consis-
tent with prior studies (Holt et al. 1981;
Swirski et al. 2002). As previously reported
(Renz et al. 1992), AHR was signiﬁcantly ele-
vated in OVA mice relative to non-OVA mice.
However, the AHR of EO mice was increased
signiﬁcantly relative to AO mice, demonstrat-
ing an ETS-dependent exacerbation of AHR
to initial allergen exposure. This exacerbation
was independent of classical inﬂammatory or
Th2 end points, an occurrence that has been
previously described (Barrett et al. 2002). As
was the case in 6-week-old ETS mice,
10-week-old ES mice demonstrated a signiﬁ-
cant increase in AHR compared with AS mice
at the highest methacholine dose. Again, this
was not sufﬁcient to create a signiﬁcant differ-
ence in the total response curve. 
Without subsequent provocation, in utero
ETS does not alter basic lung histology as evi-
denced by the lack of significant differences
between ETS and AIR mice (6 weeks) and ES
and AS mice (10 weeks). However, the AHR
increase in ETS groups at our maximum
methacholine challenge suggests that AHR
has been enhanced by ETS exposure. This is
supported by subsequent increases in AHR
following respiratory challenge with OVA
(EO versus AO).
At 15 weeks of age, after OVA sensitiza-
tion and challenge, ESO and ASO mice were
the most responsive, as reﬂected by increased
Th2 and inﬂammatory cytokines, respiratory
eosinophilia, AHR, and OVA-specific IgE.
The EOO and AOO mice were OVA-tolerant
with regard to cytokines, IgE, and airway
inﬂammatory markers, especially when com-
pared with ESO and ASO mice. Overall,
EOO mice were significantly less responsive
than AOO mice in AHR, inflammatory
cytokines, and BAL eosinophils and neu-
trophils. ASO mice exhibited classical markers
of airway inflammation but no increased
AHR. AOO mice had no signs of airway
inﬂammation but had increased AHR. These
results, combined with those of 10-week-old
EO mice, support the conclusion that adap-
tive and innate immune factors may be sufﬁ-
cient, but are not essential, for enhanced AHR
in this murine asthma model. In addition, the
results at 10 and 15 weeks demonstrate that
in utero ETS exposure aggravates AHR follow-
ing initial exposure to OVA, regardless of the
route of OVA administration.
Pair-wise comparisons of group means at
15 weeks (Table 2) revealed signiﬁcant differ-
ences for some responses of EOO compared
with AOO mice (e.g., BAL differentials,
cytokines, AHR) and some responses of ESO
versus ASO (e.g., BAL differentials and
AHR). However, in all cases, responses were
most attenuated for EOO mice and most
pronounced for ESO mice. 
The Wilcoxon test on paired sign data
conﬁrmed that responses in EOO mice were
uniformly lower (p = 0.001) than in AOO
mice, indicative of a significant trend. This
was further strengthened by a Pearson correla-
tion value of 0.96 and a ranked regression
yielding an adjusted R2 of 0.91. This analysis
supports the conclusion that exposure to ETS
in utero suppressed responses to OVA sensiti-
zation/challenge in mice previously exposed to
OVA. The Wilcoxon test on paired sign data
also demonstrated that responses in ESO mice
were consistently higher (p = 0.001) across all
data compared with responses in ASO mice.
This trend was further supported by a Pearson
correlation value of 0.99 and a ranked regres-
sion yielding an adjusted R2 of 0.98. These
results support the conclusion that in utero
ETS exposure exacerbates subsequent adult
responses to initial allergen exposure.
At 15 weeks of age, ESO mice had
enhanced initial responses to OVA sensitiza-
tion and challenge, whereas EOO mice had
dampened responses upon reexposure to OVA.
The reason for this response divergence is not
intuitively obvious. The end point measured in
ESO is, indeed, an initial response to OVA.
However, because of the “memory” inherent to
adaptive immune responses, the measurement
in EOO mice at 15 weeks is a secondary
response reflecting the initial response to
aerosol OVA at 10 weeks. Although that expo-
sure was without adjuvant, establishment of
tolerance to OVA is expected. In the case of
EOO, the decreased responsiveness at
15 weeks implies increased resistance to OVA
sensitization and challenge. Our data do not
support a role for in utero ETS in determining
the type (sensitization or tolerance) of immune
response to allergen. However, in utero ETS
appears to significantly influence the magni-
tude of response, which may increase sensitiv-
ity to allergen or severity of disease.
Adult exposure to diesel exhaust particles,
another major environmental combustion
product, has been linked with increased inci-
dence of allergies and asthma (Davies et al.
1998; Peterson and Saxon 1996), and rodent
studies have conﬁrmed that diesel exhaust par-
ticles promote allergic and asthmatic immune
responses (Nel et al. 1998; Pandya et al. 2002).
These adult studies suggest that environmental
exposures do not cause immune deviation but
have an adjuvant-like effect on immune
response to allergen. We demonstrate that, in
addition to aggravating AHR, in utero ETS
exposure promotes initial immune responses to
allergen sensitization and challenge in adults
(ESO vs. ASO). 
Residual oil fly ash (ROFA) overcomes
aerosol tolerance in young mice if the ROFA
and OVA exposures are simultaneous (Hamada
et al. 2000). Similarly, concurrent administra-
tion of inhaled OVA and Th2-adjuvant pre-
vented establishment of OVA-specific IgE
tolerance (Hurst et al. 2001). Once tolerance
had been established, however, it could not be
completely overcome by later simultaneous
administration of OVA and the Th2 response-
provoking agents. The latter finding is sup-
ported by our results, where tolerance resulting
from OVA aerosol at 7–8 weeks of age per-
sisted at least 8 weeks and was not overcome by
in utero ETS exposure. In fact, the dampened
responses of adult EOO mice suggest increased
resistance to sensitization and challenge. These
results are consistent with recent reports that
smoking-associated AHR increases can occur
independent of changes in levels of Th2
cytokines and IgE (Robbins et al. 2005), and
that smoking-allergen interactions may be
allergen-speciﬁc (Jarvis et al. 1999). 
Although the mechanism underlying the
ETS-mediated responses to initial OVA expo-
sure has not been identified, preliminary
results point to the involvement of arginase-1
(ARG1) in this process. Up-regulation of
ARG1 has been identiﬁed as an important step
in the pathophysiology of asthma (Erdely et al.
2006; Zimmerman et al. 2003; Zimmermann
and Rothenberg 2006). Nitric oxide produc-
tion, which is vital for relaxation of airway
smooth muscle cells, depends critically on the
presence of adequate levels of arginine. Up-
regulation of ARG1 leads to increased catabo-
lism of arginine, decreased NO production,
and subsequently increased AHR. Consistent
with this, polymerase chain reaction analysis
revealed that ARG1 was up-regulated in lungs
of ESO versus EOO mice at 15 weeks (Penn
et al., unpublished data).
The results of this 15-week study indicate
that in utero ETS suppresses adult responses
to repeated exposures of the same antigen
In utero ETS potentiates adult allergic responses
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Table 2. Paired-means of treatment groups used for trend analysis. 
BAL cytokinesa BAL Methacholine (mg/mL)b  Pathc  Antibodiesd
IL-13 IL-4 IL-5 TNF-α Eos (%)  12.5  25 50  score IgG1 IgE
ESO versus ASO
ESO 4.46 48.82 26.43 31.96 50.0 2.86 4.90 7.68 19.3 1.28 0.20
ASO 3.18 39.79 18.37 21.53 23.0 1.74 3.20 4.04 17.7 0.46 0.18
EOO versus AOO
EOO 1.000 20.14 1.17 11.56 1.5 1.51 2.31 4.05 10.4 0.90 0.08
AOO 2.300 42.76 7.24 31.45 11.9 2.28 4.00 7.62 12.8 1.00 0.13
Eos, eosinophils. aBAL cytokines are ranked values. bAHR is expressed as an index value, Penh, at three methacholine con-
centrations. cCumulative histopathologic index value. dExpressed in EU. (EOO), but it also aggravates adult responses
to initial antigen exposure (EO at 10 weeks of
age and ESO at 15 weeks). If this heightened
sensitivity extends beyond OVA to unrelated
antigens, as seems likely, mice exposed in utero
to ETS and then to other antigens as adults
(e.g., Aspergillus, cockroach antigen, bacterial
lipopolysaccharide, respiratory viruses) would
have exaggerated responses compared with
mice not exposed in utero to ETS. 
Conclusion 
Four main conclusions emerge from this
investigation: 
• In utero ETS exposure alone does not alter
respiratory structure or function in healthy
mice. 
• In utero ETS exposure exacerbates initial
adult responses to allergen as demonstrated
by the EO versus AO at 10 weeks (AHR)
and the entire range of ESO versus ASO
responses at 15 weeks. This effect is inde-
pendent of whether OVA is first encoun-
tered as a tolerizing aerosol (EO at 10 weeks)
or as part of a sensitization and challenge
protocol (ESO at 15 weeks). 
• In this model, increased AHR upon initial
allergen exposure is not necessarily coupled
with changes in histopathology, cytokine
proﬁle, or antibody levels (compare responses
after OVA exposure at 10 vs. 15 weeks) but
is related to in utero ETS exposure. AHR is
sometimes the only significant finding.
Coincidentally, in human asthmatic episodes,
AHR is the preliminary clinical response and
often the only initial ﬁnding.
• Finally, OVA tolerance is not overcome by
in utero ETS exposure.
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